Identification of (beta-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor gamma activity
- Authors
- Choi, Jiwon; Ko, Yoonae; Lee, Hui Sun; Park, Yun Sun; Yang, Young; Yoon, Sukjoon
- Issue Date
- Jan-2010
- Publisher
- ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
- Keywords
- Rhodanine; Peroxisome proliferators-activated receptor (PPAR); Thiazolidinedione (TZD); Computer-aided drug discovery, Molecular docking, Binding mode analysis
- Citation
- EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v.45, no.1, pp 193 - 202
- Pages
- 10
- Journal Title
- EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Volume
- 45
- Number
- 1
- Start Page
- 193
- End Page
- 202
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/13297
- DOI
- 10.1016/j.ejmech.2009.09.042
- ISSN
- 0223-5234
1768-3254
- Abstract
- We applied an improved virtual screening scheme combining ligand-centric and receptor-centric methods for the identification of a new series of PPAR gamma agonists known as (beta-carboxyethyl)-rhodanine derivatives which include a thiazolidin-based core structure, 2-thioxo-thiazolidine-4-one. An in vitro assay confirmed the nanomolar binding affinity in one of the (beta-carboxyethyl)-rhodanine derivatives, SP1818. It showed a PPAR gamma agonistic activity similar to that of a known PPAR gamma drug, pioglitazone, in a cell-based transactivation assay. Furthermore, the structure-activity relationships of the rhodanine derivatives were investigated through comparative molecular field analysis. We also characterized the inconsistency between the in vitro binding affinity and cell-based transactivation ability by using a set of property-based molecular descriptors. The binding mode analysis provided new insight concerning their agonistic effect on PPAR gamma. (C) 2009 Elsevier Masson SAS. All rights reserved.
- Files in This Item
-
Go to Link
- Appears in
Collections - 이과대학 > 생명시스템학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.